Galapagos Set to Announce Q4 Earnings on February 23
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 20 2026
0mins
Should l Buy GLPG?
Source: seekingalpha
- Earnings Announcement Schedule: Galapagos is set to release its Q4 2023 earnings report on February 23 before market open, with a consensus EPS estimate of $1.34, reflecting a 19.6% year-over-year improvement, indicating enhanced profitability.
- Revenue Expectations Decline: Despite the positive EPS outlook, the revenue estimate stands at $80.75 million, representing a significant 70.7% year-over-year decline, highlighting substantial challenges in revenue growth that may affect investor confidence.
- Strategic Shift: Galapagos is pivoting from clinical risk management to strategic capital allocation, aiming to optimize resource distribution to support the development of its rare autoimmune disease assets, demonstrating a commitment to future growth.
- Clinical Research Progress: The company has met its primary goal in a pivotal phase 3 study, which could bolster the market prospects for its rare disease treatment products and enhance investor confidence in its R&D capabilities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GLPG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GLPG
Wall Street analysts forecast GLPG stock price to rise
4 Analyst Rating
1 Buy
1 Hold
2 Sell
Hold
Current: 28.840
Low
22.00
Averages
30.50
High
40.00
Current: 28.840
Low
22.00
Averages
30.50
High
40.00
About GLPG
Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. It develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve of life of patients across the globe. It discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The Company acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Galapagos Enters Strategic Collaboration with Gilead
- Strategic Collaboration Agreement: Galapagos has signed a framework agreement with Gilead, which will acquire Ouro Medicines for $1.675 billion, allowing Galapagos to secure 50% of the upfront cash and milestone payments, enhancing its financial flexibility for future strategic transactions.
- Cash Reserve Advantage: Following this transaction, Galapagos will retain $500 million in cash for independent investments and potential share buybacks of up to $150 million, ensuring the company remains competitive in the rapidly evolving biotech market.
- Clinical Innovation Potential: Gamgertamig, a next-generation T cell engager, has demonstrated significant efficacy in clinical trials and is expected to enter registrational studies by 2027, potentially becoming the preferred treatment for autoimmune diseases, addressing the urgent market demand for new therapies.
- Market Outlook: The CEO of Galapagos stated that this collaboration not only brings in a high-potential asset but also leverages Gilead's global commercial capabilities to accelerate the development of Gamgertamig, which is expected to provide better treatment options for patients and drive long-term growth for the company.
See More
Galapagos Enters Binding Agreement with Gilead for Acquisition
- Acquisition Agreement Details: Under the binding framework agreement with Gilead, Galapagos will receive 50% of the total acquisition consideration, amounting to $1.675 billion in upfront payments and any contingent milestone payments, highlighting its strategic significance in the biotech sector.
- Flexible Capital Utilization: The agreement allows Galapagos to deploy at least $500 million of its cash independently, including up to $150 million for share buybacks, enhancing its capital management flexibility and market confidence.
- Intellectual Property Licensing: The framework includes licenses for certain intellectual property rights related to Ouro's research programs, enabling Galapagos to acquire nearly all of Ouro's operational assets, thereby enriching its product pipeline, particularly in autoimmune disease projects.
- Potential Milestone Earnings: Galapagos is eligible for up to $100 million in milestone payments upon Gilead's initiation of registrational trials for gamgertamig, and will receive tiered royalties of 20-23% on net sales post-commercialization, indicating significant future revenue growth potential.
See More
Galapagos Enters Binding Agreement with Gilead for Ouro Medicines Acquisition
- Acquisition Agreement Details: Galapagos NV has entered into a binding agreement with Gilead Sciences, which will acquire all equity interests of Ouro Medicines for $1.675 billion, allowing Galapagos to secure 50% of the upfront consideration and milestone payments, ensuring sufficient funds for future strategic transactions.
- Product Development Progress: Gamgertamig, a clinical-stage T cell engager, has received Fast Track and Orphan Drug Designation from the FDA and is expected to enter registrational studies by 2027, highlighting its potential in treating autoimmune diseases.
- Cost Sharing Arrangement: Under the agreement, Galapagos will bear all pre-registration development costs for Gamgertamig, including Ouro's clinical trials, while registration-enabling clinical development costs will be shared equally, ensuring effective resource utilization.
- Commercialization Revenue: Gilead will be responsible for the global commercialization of Gamgertamig, with Galapagos entitled to tiered royalties of 20-23% on net sales, which is expected to generate substantial long-term revenue and enhance its market position.
See More
Gilead to Acquire Ouro Medicines for $2.18B, Expanding Inflammation Pipeline
- Acquisition Details: Gilead Sciences plans to acquire Ouro Medicines for approximately $2.18 billion, which includes $1.68 billion in cash and up to $500 million in contingent milestone payments, significantly enhancing its inflammation drug pipeline.
- R&D Collaboration Potential: Gilead's partnership with Galapagos NV will allow both companies to share trial costs, with Galapagos funding half of the upfront payment and milestone obligations, further advancing research in autoimmune diseases.
- New Drug Prospects: The acquisition will provide Gilead with gamgertamig, a drug showing efficacy in severe antibody-mediated orphan diseases in ongoing Phase 1/2 studies, expected to enter late-stage studies by 2027, indicating strong market potential.
- Market Strategy Expansion: Gilead's CMO stated that this acquisition is a crucial step in expanding treatment options for autoimmune diseases, likely enhancing its competitive position in the biopharmaceutical market while retaining most global commercialization rights and paying royalties of 20% to 23%.
See More
Tesla Sees Sales Rebound in Europe and China
- European Sales Rebound: Tesla recorded nearly a 12% increase in monthly new car registrations in Europe, ending a 14-month sales slump, which demonstrates its adaptability in the face of competition from Chinese EV rivals and may bolster investor confidence.
- Strong Chinese Market: Recent data shows Tesla's retail sales in China surged over 42% year-over-year, indicating robust demand in the global EV market, which could positively impact future revenue growth.
- Intensifying Market Competition: Despite the sales rebound, competitor BYD saw registrations nearly triple in February, highlighting the fierce competition in the EV market, necessitating Tesla's continuous innovation to maintain market share.
- Analyst Rating Adjustments: HSBC analyst lowered Tesla's price target to $119 while maintaining a 'reduce' rating, reflecting market concerns over future demand, which may exert short-term pressure on the stock price.
See More
Gilead Acquires Ouro to Enhance Portfolio
- Ouro Acquisition: Gilead Sciences has announced a $2.18 billion acquisition of Ouro Medicines to enhance its inflammation portfolio, underscoring its commitment to advancing transformative therapies, with Ouro's key drug gamgertamig already in the FDA fast-track process.
- Sales Growth Outlook: Analysts project Gilead's product sales to approach or exceed $30 billion in 2026, indicating significant growth potential in the market, and the acquisition is expected to further drive business development.
- Tesla's European Recovery: Tesla recorded its first monthly sales increase in Europe in over a year, with nearly a 12% rise, ending a 14-month slump, demonstrating its competitive edge against Chinese EVs, while the overall EV market grew by almost 16%.
- AI Infrastructure Bottlenecks: Broadcom has warned of supply chain constraints in the AI infrastructure sector, which could hinder industry growth, particularly as demand for AI chips surges, with capacity limitations at key manufacturers like Taiwan Semiconductor potentially leading to longer lead times.
See More
Galapagos Enters Strategic Collaboration with Gilead
- Strategic Collaboration Agreement: Galapagos has signed a framework agreement with Gilead, which will acquire Ouro Medicines for $1.675 billion, allowing Galapagos to secure 50% of the upfront cash and milestone payments, enhancing its financial flexibility for future strategic transactions.
- Cash Reserve Advantage: Following this transaction, Galapagos will retain $500 million in cash for independent investments and potential share buybacks of up to $150 million, ensuring the company remains competitive in the rapidly evolving biotech market.
- Clinical Innovation Potential: Gamgertamig, a next-generation T cell engager, has demonstrated significant efficacy in clinical trials and is expected to enter registrational studies by 2027, potentially becoming the preferred treatment for autoimmune diseases, addressing the urgent market demand for new therapies.
- Market Outlook: The CEO of Galapagos stated that this collaboration not only brings in a high-potential asset but also leverages Gilead's global commercial capabilities to accelerate the development of Gamgertamig, which is expected to provide better treatment options for patients and drive long-term growth for the company.
See More
Galapagos Enters Binding Agreement with Gilead for Acquisition
- Acquisition Agreement Details: Under the binding framework agreement with Gilead, Galapagos will receive 50% of the total acquisition consideration, amounting to $1.675 billion in upfront payments and any contingent milestone payments, highlighting its strategic significance in the biotech sector.
- Flexible Capital Utilization: The agreement allows Galapagos to deploy at least $500 million of its cash independently, including up to $150 million for share buybacks, enhancing its capital management flexibility and market confidence.
- Intellectual Property Licensing: The framework includes licenses for certain intellectual property rights related to Ouro's research programs, enabling Galapagos to acquire nearly all of Ouro's operational assets, thereby enriching its product pipeline, particularly in autoimmune disease projects.
- Potential Milestone Earnings: Galapagos is eligible for up to $100 million in milestone payments upon Gilead's initiation of registrational trials for gamgertamig, and will receive tiered royalties of 20-23% on net sales post-commercialization, indicating significant future revenue growth potential.
See More
Galapagos Enters Binding Agreement with Gilead for Ouro Medicines Acquisition
- Acquisition Agreement Details: Galapagos NV has entered into a binding agreement with Gilead Sciences, which will acquire all equity interests of Ouro Medicines for $1.675 billion, allowing Galapagos to secure 50% of the upfront consideration and milestone payments, ensuring sufficient funds for future strategic transactions.
- Product Development Progress: Gamgertamig, a clinical-stage T cell engager, has received Fast Track and Orphan Drug Designation from the FDA and is expected to enter registrational studies by 2027, highlighting its potential in treating autoimmune diseases.
- Cost Sharing Arrangement: Under the agreement, Galapagos will bear all pre-registration development costs for Gamgertamig, including Ouro's clinical trials, while registration-enabling clinical development costs will be shared equally, ensuring effective resource utilization.
- Commercialization Revenue: Gilead will be responsible for the global commercialization of Gamgertamig, with Galapagos entitled to tiered royalties of 20-23% on net sales, which is expected to generate substantial long-term revenue and enhance its market position.
See More
Gilead to Acquire Ouro Medicines for $2.18B, Expanding Inflammation Pipeline
- Acquisition Details: Gilead Sciences plans to acquire Ouro Medicines for approximately $2.18 billion, which includes $1.68 billion in cash and up to $500 million in contingent milestone payments, significantly enhancing its inflammation drug pipeline.
- R&D Collaboration Potential: Gilead's partnership with Galapagos NV will allow both companies to share trial costs, with Galapagos funding half of the upfront payment and milestone obligations, further advancing research in autoimmune diseases.
- New Drug Prospects: The acquisition will provide Gilead with gamgertamig, a drug showing efficacy in severe antibody-mediated orphan diseases in ongoing Phase 1/2 studies, expected to enter late-stage studies by 2027, indicating strong market potential.
- Market Strategy Expansion: Gilead's CMO stated that this acquisition is a crucial step in expanding treatment options for autoimmune diseases, likely enhancing its competitive position in the biopharmaceutical market while retaining most global commercialization rights and paying royalties of 20% to 23%.
See More
Tesla Sees Sales Rebound in Europe and China
- European Sales Rebound: Tesla recorded nearly a 12% increase in monthly new car registrations in Europe, ending a 14-month sales slump, which demonstrates its adaptability in the face of competition from Chinese EV rivals and may bolster investor confidence.
- Strong Chinese Market: Recent data shows Tesla's retail sales in China surged over 42% year-over-year, indicating robust demand in the global EV market, which could positively impact future revenue growth.
- Intensifying Market Competition: Despite the sales rebound, competitor BYD saw registrations nearly triple in February, highlighting the fierce competition in the EV market, necessitating Tesla's continuous innovation to maintain market share.
- Analyst Rating Adjustments: HSBC analyst lowered Tesla's price target to $119 while maintaining a 'reduce' rating, reflecting market concerns over future demand, which may exert short-term pressure on the stock price.
See More
Gilead Acquires Ouro to Enhance Portfolio
- Ouro Acquisition: Gilead Sciences has announced a $2.18 billion acquisition of Ouro Medicines to enhance its inflammation portfolio, underscoring its commitment to advancing transformative therapies, with Ouro's key drug gamgertamig already in the FDA fast-track process.
- Sales Growth Outlook: Analysts project Gilead's product sales to approach or exceed $30 billion in 2026, indicating significant growth potential in the market, and the acquisition is expected to further drive business development.
- Tesla's European Recovery: Tesla recorded its first monthly sales increase in Europe in over a year, with nearly a 12% rise, ending a 14-month slump, demonstrating its competitive edge against Chinese EVs, while the overall EV market grew by almost 16%.
- AI Infrastructure Bottlenecks: Broadcom has warned of supply chain constraints in the AI infrastructure sector, which could hinder industry growth, particularly as demand for AI chips surges, with capacity limitations at key manufacturers like Taiwan Semiconductor potentially leading to longer lead times.
See More
